Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from development-stage operations to commercial scale. Burcon's Galesburg production facility is now operational, generating $739,000 in revenue for the third quarter of fiscal year 2026, representing approximately 107% quarter-over-quarter growth driven by protein sales and production activity.
The company entered calendar year 2025 without a production facility and exited the year meeting its revenue target, underscoring the speed of commercialization following Galesburg's launch. Management indicated that staffing and infrastructure are now in place, positioning incremental volume growth to occur with limited additional fixed costs. This setup supports operating leverage as throughput increases.
Importantly, once a customer's product is commercialized, ingredient purchases typically recur on a month-to-month basis. With approximately 65–70% of expected growth tied to customers already purchasing and over 200 active projects in the pipeline, Galesburg serves as the backbone of durable, recurring revenue expansion. Revenue increased 1,100% year-over-year, and double-digit revenue is expected in calendar year 2026.
For more details, view the full announcement here.
About Stonegate: Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies.
